HIV-1's 'hijacking mechanism' pinpointed by McGill/JGH researchersJune 11, 2009Researchers at McGill University and the affiliated Lady Davis Institute for Medical Research at Montreal's Jewish General Hospital - along with colleagues at the University of Manitoba and the University of British Columbia - may have found a chink in the armour of the human immunodeficiency virus type 1 (HIV-1), the microorganism which causes AIDS. They have pinpointed the key cellular machinery co-opted by HIV-1 to hijack the human cell for its own benefit. Their study was published in May in the Journal of Biological Chemistry. Once a cell is infected with HIV-1, activation of the virus's gene generates a large HIV-1 RNA molecule known as the RNA genome. This is then transported from the cell nucleus to the inner surface of the plasma membrane. The RNA genome can produce both structural proteins and enzymes, but once it arrives at the plasma membrane it can also assemble into new copies of the virus that actually bud out of the cell. Dr. Andrew J. Mouland and his colleagues have discovered how the RNA genome gets transported - or trafficked - from the nucleus to the plasma membrane. "There is a highway inside the human cell," explained Dr. Mouland, Associate Professor at McGill's Departments of Medicine and Microbiology and Immunology and head of the HIV-1 RNA Trafficking Laboratory at the Lady Davis Institute. "When you drive your car to Toronto you're 'trafficking' the items in your trunk. Similarly, what we have shown is that HIV-1 commandeers the host cell's endosomal machinery to traffic its structural proteins and RNA genome. Imagine that it's essentially jumping on board for the ride and directing it to where it needs to go. This trafficking can occur very fast in cells; so this is how these key components of HIV-1 so efficiently get to the plasma membrane, where the virus can begin to assemble. "The RNA genome is critical, because if it doesn't get trafficked to the right place at the plasma membrane, the virus will not be infectious," he explained. This discovery is extremely exciting, Dr. Mouland said, because now that researchers understand a little more about how the cell's transport machinery is hijacked by HIV-1, they have hopes that they can now begin to devise strategies to block the process. McGill University |
|||||||||||||||||||||
| Related HIV-1 Current Events and HIV-1 News Articles Maternal HIV-1 treatment protects against transmission to newborns Mothers receiving highly active antiretroviral therapy (HAART) to treat HIV-1 infection are less likely than untreated mothers to transmit the virus to their newborns through breastfeeding. Scientists join forces to explain HIV spread in Central and East Africa Scientists studying biology and geography may seem worlds apart, but together they have answered a question that has defied explanation about the spread of the HIV-1 epidemic in Africa. Researchers induce HIV-neutralizing antibodies that recognize HIV-1 envelope protein, lipids For the first time, researchers have experimentally induced antibodies that neutralize HIV-1 and simultaneously recognize both HIV-1 envelope protein and lipids. Link uncovered between viral RNA and human immune response In its fight against an intruding virus, an enzyme in our immune system may sense certain types of viral RNA pairs, according to scientists. In vitro antibody production enables HIV infection detection in window period -- key to safer blood Researchers in Israel and Kenya have shown that the contribution of variable degrees of immune suppression, either due to existing chronic infections such as parasitemias and/or nutrition, in different populations may influence and prolong the serological-diagnostic window period of HIV. AIDS discovered in wild chimpanzees Although the AIDS virus (HIV-1) entered the human population through chimpanzees, scientists have long believed that chimpanzees don't develop AIDS. Penn-Wistar team gains insight into HIV vaccine failure A team of researchers from The Wistar Institute and the University of Pennsylvania reports new evidence refuting a popular hypothesis about the highly publicized failure in 2007 of the Merck STEP HIV vaccine study that cast doubt on the feasibility of HIV-1 vaccines. Genetic Variation Associated With Survival Advantage in African Americans With HIV From the start of the HIV epidemic, it appeared that some of the people who were infected with the virus were able to ward off the fatal effects of the disease longer than others. Study offers insights into failed HIV-1 vaccine trial Following the disbandment of the STEP trial to test the efficacy of the Merck HIV-1 vaccine candidate in 2007, the leading explanation for why the vaccine was ineffective - and may have even increased susceptibility to acquiring the virus - centered on the hypothesis that high levels of baseline Ad5-specific neutralizing antibodies may have increased HIV-1 acquisition among the study subjects who received the vaccine by increasing Ad5-specific CD4+ T-cells that were susceptible to HIV-1 infection. Gladstone scientists identify key factor that controls HIV latency Scientists at the Gladstone Institutes of Virology and Immunology (GIVI) have found another clue that may lead to eradication of HIV from infected patients who have been on antiretroviral therapy. More HIV-1 Current Events and HIV-1 News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||